Abstract C153: Therapeutic peptides in oncology: Current landscape and future directions
Abstract
Highlight · Therapeutic peptides are emerging as a versatile class of anticancer agents, offering high target specificity, favorable safety profiles, and diverse applications ranging from direct tumor killing and immune modulation to targeted drug delivery and cancer theragnostic. · Repurposed viral-derived peptides represent a promising new frontier in oncology, exemplified by the HIV-1 Secretory/Signal Motif Region (SMR) peptide, which demonstrates antitumor activity in aggressive and therapy-resistant cancer models and highlights the potential of exploiting viral–host interaction motifs as novel cancer therapeutic targets. Abstract Therapeutic peptides have emerged as a versatile and rapidly expanding class of anticancer agents that bridge key limitations of conventional small-molecule drugs and biologics. Owing to their high target specificity, favorable safety profiles, and structural tunability, peptides are increasingly being developed for applications spanning direct tumor cytotoxicity, receptor-mediated targeting, immune modulation, and precision delivery of therapeutics and imaging agents. Recent advances in peptide chemistry, computational design, and drug-delivery technologies have overcome longstanding challenges related to stability, pharmacokinetics, and intracellular access, accelerating the clinical translation of peptide-based strategies in oncology. In this review, we provide an overview of the current landscape of therapeutic peptides in cancer, highlighting major functional classes—including anticancer peptides, receptor-targeting ligands, peptide–drug conjugates, and peptide-based theragnostic platforms—and discussing their mechanisms of action and clinical progress. We further examine emerging design and delivery innovations that are reshaping peptide utility in precision oncology. Notably, we highlight the growing interest in repurposed bioactive peptides, including those derived from viral proteins, as a novel and underexplored source of anticancer therapeutics. In this context, we discuss our group’s development of the HIV-1 Secretory/Signal Motif Region (SMR) peptide, a viral-derived peptide repurposed for oncology applications, which demonstrates antitumor activity in aggressive and therapy-resistant cancer models. This example highlights the potential of leveraging viral–host interaction motifs to target non-canonical cancer vulnerabilities. Ming Bo B. Huang, Uswa B. Jadoon, Jennifer Y. Wu, Dara Brena, Aykut Uren, Fengxia B. Yan, Erica L. Johnson, Jonathan B. Stiles, Brian M. Rivers, Vincent C. Bond. Therapeutic peptides in oncology: Current landscape and future directions [abstract]. In: Proceedings of the 19th AACR Conference on the Science of Cancer Health Disparities; 2026 Oct 18-21; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2026;35(10 Suppl):Abstract nr C153.